SCHEMBL6328657

SCHEMBL6328657

Cc1cc(CC(=O)NCCCN2CCCC2)c(/C=C2\C(=O)Nc3cccc(-c4cccc(F)c4)c32)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 6/20 0.46
KDR P35968 6/20 0.46
FGFR1 P11362 3/20 0.46
TLK2 Q86UE8 1/20 0.46
FLT3 P36888 4/20 0.42
FLT1 P17948 3/20 0.42
CSF1R P07333 2/20 0.42
PDGFRA P16234 1/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
KIT P10721 3/20 0.41
PIM1 P11309 3/20 0.41
PIM2 Q9P1W9 2/20 0.41
ALK Q9UM73 2/20 0.41
SMYD2 Q9NRG4 1/20 0.41
CHEK1 O14757 2/20 0.39
KMT2A Q03164 1/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321236 0.96 PDGFRB (0.51) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL6329410 0.86 PDGFRB (0.49) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL6323841 0.84 PDGFRB (0.57) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL6324172 0.81 SMYD2 (0.47) PDGFRBKDRFGFR1TLK2FLT1
SCHEMBL6321318 0.81 FLT1 (0.45) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL6321930 0.80 FLT1 (0.42) PDGFRBKDRFGFR1FLT3FLT1
SCHEMBL6329305 0.80 MET (0.43) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL6766495 0.79 PDGFRB (0.42) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL6322958 0.79 KDR (0.46) PDGFRBKDRFGFR1TLK2FLT3
SCHEMBL6322518 0.79 FLT1 (0.41) PDGFRBKDRFGFR1TLK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 PDGFRB 575/4885KDR 819/4885FGFR1 525/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 PDGFRB 575/4885KDR 819/4885FGFR1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.